18:31 , Oct 6, 2017 |  BC Week In Review  |  Clinical News

Motif's iclaprim meets in second Phase III for ABSSSIs

Motif Bio plc (LSE:MTFB; NASDAQ:MTFB) reported top-line data showing that iclaprim (MTF-100) met the primary endpoint of non-inferiority to vancomycin in the Phase III REVIVE-2 trial to treat acute bacterial skin and skin structure infections...
21:08 , Apr 27, 2017 |  BC Week In Review  |  Clinical News

Iclaprim: Ph III REVIVE-1 data

Top-line data from the double-blind, international Phase III REVIVE-1 trial in 598 patients with ABSSSIs showed that 80 mg IV iclaprim every 12 hours for 5-14 days met the primary endpoint of non-inferiority to vancomycin...
08:00 , Mar 7, 2016 |  BC Week In Review  |  Clinical News

Iclaprim: Phase III started

Motif began the identical, double-blind, international Phase III REVIVE-1 and REVIVE-2 trials to evaluate IV iclaprim twice daily for 5-14 days vs. IV vancomycin in about 1,200 total patients. FDA issued a complete response letter...
07:00 , Sep 14, 2015 |  BC Week In Review  |  Clinical News

Iclaprim regulatory update

FDA granted Fast Track designation to IV iclaprim from Motif Bio to treat acute bacterial skin and skin structure infections (ABSSSIs) and hospital-acquired bacterial pneumonia (HABP). This half, Motif plans to start Phase III trials...
07:00 , Sep 7, 2015 |  BC Week In Review  |  Clinical News

Motif Bio preclinical data

In vitro, the minimum inhibitory concentration of iclaprim with antimicrobial activity against 50% (MIC50) and 90% (MIC90) of isolates was 0.06 and 0.12 ug/mL, respectively. The broad-spectrum antibiotic that inhibits dihydrofolate reductase (DHFR) was tested...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Clinical News

Iclaprim regulatory update

FDA granted Qualified Infectious Disease Product (QIDP) designation to iclaprim from Motif to treat hospital-acquired bacterial pneumonia (HABP) and acute bacterial skin and skin structure infections (ABSSSIs). Motif has not yet determined a development timeline...
00:10 , Jul 18, 2015 |  BC Extra  |  Company News

QIDP for Motif's iclaprim triggers L22M placing

FDA granted Qualified Infectious Disease Product (QIDP) designation to iclaprim from Motif Bio plc (LSE:MTFB) to treat hospital-acquired bacterial pneumonia (HABP), triggering a L22 million ($34.1 million) placing. Motif sold 44 million shares at 50p...
08:00 , Dec 21, 2009 |  BC Week In Review  |  Company News

Arpida, Evolva deal

Evolva and Arpida completed their previously announced reverse merger. The newco was renamed Evolva Holding S.A. (SIX:EVE) (see BioCentury, Sept. 14). Arpida Ltd. , Reinach, Switzerland   Evolva S.A. , Allschwil, Switzerland   Business: Infectious,...
08:00 , Dec 21, 2009 |  BC Week In Review  |  Financial News

Evolva financial update

Evolva raised CHF21 million ($20.4 million) in a second close of a series B round, bringing the total raised in the round to CHF49 million ($48 million). New investor Entrepreneurs Fund joined existing investors Novartis...
08:00 , Dec 21, 2009 |  BioCentury  |  Finance

Ebb & Flow

The 2004 merger of Fujisawa Pharmaceutical Co. Ltd. and Yamanouchi Pharmaceutical Co. Ltd. to form Astellas Pharma Inc . (Tokyo:4503) has led to big payoffs in the last two weeks for Calixa Therapeutics Inc. and...